Germany-headquartered CNS drug specialist Neuraxpharm today revealed that UK health technology assessor the National ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces that the National Institute for ...

New Delhi: Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

Trastuzumab deruxtecan is a targeted drug used to treat certain types of cancer: breast cancer, gastric or gastroesophageal ...

The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products ...

The Food and Drug Administration (FDA) has expanded the list of medicines exempted from value-added tax (VAT) to ensure ...

Boston Scientific (NYSE:BSX) announced today that it agreed to acquire infusion pump maker Intera ... and we are committed to providing meaningful solutions to safely and effectively treat various ...

The Subject Expert Committee (SEC), under the Central Drugs Standard Control Organisation (CDSCO), has recommended approval of additional indication of US-based Bristol-Myers Squibb's anti-cancer drug ...

Gohibic will be available in the form of a 200 mg concentrate for solution for infusion. The committee specified that injection with Gohibic should be initiated and monitored by a physician ...

Baxter International Inc. BAX 0.27% is in advanced talks to buy medical-equipment maker Hill-Rom Holdings Inc. HRC 0.96% for around $10 billion, according to people familiar with the matter.

The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, ...